Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. BRNS
stocks logo

BRNS

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.400
-21.57%
--
--
-0.360
-26.53%
--
--
-0.360
-30.77%
Estimates Revision
The market is revising No Change the revenue expectations for Barinthus Biotherapeutics plc (BRNS) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -41.85%.
EPS Estimates for FY2025
Revise Upward
up Image
+1.42%
In Past 3 Month
Stock Price
Go Down
down Image
-41.85%
In Past 3 Month
Wall Street analysts forecast BRNS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BRNS is 4.00 USD with a low forecast of 4.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast BRNS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BRNS is 4.00 USD with a low forecast of 4.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.721
sliders
Low
4.00
Averages
4.00
High
4.00
Current: 0.721
sliders
Low
4.00
Averages
4.00
High
4.00
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$3 -> $4
2025-11-17
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$3 -> $4
2025-11-17
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Barinthus Biotherapeutics to $4 from $3 and keeps a Buy rating on the shares following the Q3 report.
HC Wainwright & Co.
Yi Chen
Strong Buy
Reiterates
$3
2025-03-21
Reason
HC Wainwright & Co.
Yi Chen
Price Target
$3
2025-03-21
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Yi Chen
Strong Buy
Maintains
$5 → $3
2025-01-13
Reason
HC Wainwright & Co.
Yi Chen
Price Target
$5 → $3
2025-01-13
Maintains
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Barinthus Biotherapeutics PLC (BRNS.O) is -0.49, compared to its 5-year average forward P/E of -1.17. For a more detailed relative valuation and DCF analysis to assess Barinthus Biotherapeutics PLC 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.17
Current PE
-0.49
Overvalued PE
7.78
Undervalued PE
-10.11

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.61
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
2.52
Undervalued EV/EBITDA
-3.74

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
28.89
Current PS
0.00
Overvalued PS
71.64
Undervalued PS
-13.86
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

BRNS News & Events

Events Timeline

(ET)
2025-11-07
07:33:30
Barinthus Biotherapeutics announces Q3 earnings per share of 36 cents, compared to a loss of 21 cents in the same period last year.
select
2025-09-30 (ET)
2025-09-30
08:20:53
Barinthus Bio and Clywedog Finalize Merger Agreement
select
2025-08-07 (ET)
2025-08-07
08:03:26
Barinthus Biotherapeutics sees cash runway into 2027
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
7.0
11-20Globenewswire
Halper Sadeh LLC Urges HFWA, BRNS, FITB Shareholders to Reach Out for Rights Consultation

  • Investigation of Mergers: Halper Sadeh LLC is investigating potential violations of federal securities laws related to mergers involving Heritage Financial Corporation, Barinthus Biotherapeutics plc, and Fifth Third Bancorp.

  • Shareholder Rights: The firm encourages shareholders from these companies to learn about their rights and options regarding the proposed mergers, which may affect their ownership stakes in the combined entities.

  • Legal Representation: Halper Sadeh LLC offers to represent shareholders on a contingent fee basis, meaning no upfront legal fees are required, and they aim to seek increased consideration or additional disclosures for shareholders.

  • Contact Information: Shareholders can contact Halper Sadeh LLC for free consultations regarding their legal rights, with provided contact details for attorneys Daniel Sadeh and Zachary Halper.

[object Object]
Preview
7.0
11-20PRnewswire
Halper Sadeh LLC Encourages BRNS, FITB, ADVM, HBAN Shareholders to Contact the Firm to Discuss Their Rights

  • Investigation of Companies: Halper Sadeh LLC is investigating Barinthus Biotherapeutics, Fifth Third Bancorp, Adverum Biotechnologies, and Huntington Bancshares for potential violations of federal securities laws and breaches of fiduciary duties to shareholders related to their mergers and acquisitions.

  • Shareholder Rights: Shareholders of the mentioned companies are encouraged to contact Halper Sadeh LLC to learn about their legal rights and options, as there may be limited time to enforce these rights.

  • Compensation Structure: The law firm operates on a contingent fee basis, meaning shareholders will not incur out-of-pocket legal fees unless the case is successful.

  • Legal Support for Investors: Halper Sadeh LLC represents investors globally who have experienced securities fraud and corporate misconduct, aiming to recover funds and implement corporate reforms.

[object Object]
Preview
7.0
11-18Globenewswire
Halper Sadeh LLC Urges Shareholders of HFWA, FITB, AVDL, and BRNS to Reach Out for Rights Consultation

  • Investigation of Mergers: Halper Sadeh LLC is investigating potential violations of federal securities laws related to mergers involving Heritage Financial Corporation, Fifth Third Bancorp, Avadel Pharmaceuticals, and Barinthus Biotherapeutics.

  • Shareholder Rights: Shareholders of the mentioned companies are encouraged to learn about their rights and options regarding the proposed transactions, with the firm offering legal assistance on a contingent fee basis.

  • Compensation Details: Avadel shareholders are set to receive $18.50 per share plus a potential additional payment contingent on FDA approval, while Barinthus shareholders will receive shares in the new combined company.

  • Legal Support for Investors: Halper Sadeh LLC represents investors globally, focusing on securities fraud and corporate misconduct, and has a history of recovering funds for defrauded investors.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Barinthus Biotherapeutics PLC (BRNS) stock price today?

The current price of BRNS is 0.721 USD — it has decreased -2.57 % in the last trading day.

arrow icon

What is Barinthus Biotherapeutics PLC (BRNS)'s business?

Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company focused on developing immunotherapeutic candidates for treating autoimmune and inflammatory diseases. The Company’s pipeline, built around platform technologies; viral vector-based, consists of ChAdOx and MVA, and synthetic, consisting of SNAP-Tolerance Immunotherapy (SNAP-TI). These platforms help to develop antigen-specific immunotherapeutic candidates designed to optimize the disease fighting capabilities of T cells. It is focused on developing two product candidates that harness its viral vector and synthetic platform technologies. These include VTP-300, a Phase II immunotherapeutic candidate designed as a potential component of a functional cure for chronic hepatitis B virus infection utilizing ChAdOx/MVA, and VTP-1000, its autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease. The Company's pipeline also includes VTP-850, VTP-500 and VTP-400.

arrow icon

What is the price predicton of BRNS Stock?

Wall Street analysts forecast BRNS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BRNS is 4.00 USD with a low forecast of 4.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Barinthus Biotherapeutics PLC (BRNS)'s revenue for the last quarter?

Barinthus Biotherapeutics PLC revenue for the last quarter amounts to 0.00 USD, decreased -100.00 % YoY.

arrow icon

What is Barinthus Biotherapeutics PLC (BRNS)'s earnings per share (EPS) for the last quarter?

Barinthus Biotherapeutics PLC. EPS for the last quarter amounts to -0.36 USD, increased 71.43 % YoY.

arrow icon

What changes have occurred in the market's expectations for Barinthus Biotherapeutics PLC (BRNS)'s fundamentals?

The market is revising No Change the revenue expectations for Barinthus Biotherapeutics plc (BRNS) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -41.85%.
arrow icon

How many employees does Barinthus Biotherapeutics PLC (BRNS). have?

Barinthus Biotherapeutics PLC (BRNS) has 105 emplpoyees as of December 05 2025.

arrow icon

What is Barinthus Biotherapeutics PLC (BRNS) market cap?

Today BRNS has the market capitalization of 29.44M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free